TIDUTAMAB
UNII 88635FW2QX

Substance Identification & Data

This profile provides standardized clinical and technical data for Tidutamab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 88635FW2QX.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2148354-90-7 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

88635FW2QX

CAS Registry Number

2148354-90-7

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TIDUTAMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C146820

National Cancer Institute reference terminology for clinical and research data.

INN ID

11022

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

HI-138

Identifier assigned by the United States Adopted Names Council.

Substance Type

TIDUTAMAB

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tidutamab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TIDUTAMAB

Common Names & Synonyms

ANTI-SSTR2/CD3 MONOCLONAL ANTIBODY XMAB18087

TIDUTAMAB [USAN]

Tidutamab [WHO-DD]

tidutamab [INN]

Systematic Nomenclature

IMMUNOGLOBULIN G1, ANTI-(HUMAN CD3 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB18087 .GAMMA.1-CHAIN), (265->231'),(268->234')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1, ANTI-(HUMAN SOMATOSTATIN RECEPTOR 2) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB18087 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL XMAB18087 .KAPPA.-CHAIN

SYS

IMMUNOGLOBULIN HALF-G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS SSTR2 (SOMATOSTATIN RECEPTOR 2) AND HOMO SAPIENS CD3 EPSILON (CD3E, LEU-4)), MONOCLONAL ANTIBODY, BISPECIFICGAMMA1 HEAVY CHAIN ANTI-SSTR2 (1-451) (VH (HOMO SAPIENS IGHV3-48*03 (90.8%)-(IGHD)-IGHJ4*01 (100%)) (8.8.15) (1-122)-HOMO SAPIENS IGHG1*03V (CH1 N114>D (213), R120>K (219) (123-220), HINGE 1-15 (221-235), CH2 E1.4>P (238), L1.2>V (239), G1.1>A (240), S29>K (271), Q84.2>E (299) (236-344), CH3 E12 (360), M14 (362), L24>D (372), K26>S (374), N44>D (388), Q97>E (422), N100>D (425) (345-449), CHS (450-451)) (123-451)), (225-219')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI-SSTR2 (1'-219') (V-KAPPA (HOMO SAPIENS IGKV4-1*01 (91.8%)-IGKJ4*01 (100.0%)) (12.3.8) (1'-112')-HOMO SAPIENS IGKC*01 (100%) A45.1 (158), V101 (196) (113'-219'))HEAVY CHAIN SCFV-H-CH2-CH3, ANTI-CD3E (1-485) (VH (HOMO SAPIENS IGHV3-73*01 (87.0%)-(IGHD)-IGHJ6*01 (90.9%)) (8.10.16) (1-125)-20-MER LINKER (126-145)-VLAMBDA (MUS MUSCULUS IGLV1*01 (80.6%)-IGLJ1*01 (100%)/HOMO SAPIENS IGLV7-46*01 (76.8%)-IGHJ3*02 (100%)) (9.3.9) (146-254)-IGHG1*03 (HINGE 1-15 C5>S (259) (255-269)-CH2 E1.4>P (272), L1.2>V (273), G1.1>A (274), S29>K (305) (270-378),CH3 E12 (394), E13>Q (395), M14 (396), S20>K (402)(379-483), CHS (484-485)) (1-485))(231-265'':234-268'')-BISDISULFIDE

SYS